17,261 trials
Malaria, Vivax
Primary: Efficacy of the ChAd63 and MVA PvDBP Vaccines, Administered in a Heterologous Prime-boost Regimen, Assessed by a Reduced Parasite Multiplication Rate in Vaccinated…
Contiguous Stage II Small Lymphocytic Lymphoma · Noncontiguous Stage II Small Lymphocytic Lymphoma · Stage 0 Chronic Lymphocytic Leukemia
Primary: Overall Response Rate Based on NCI-WG (for CLL) and Cheson Criteria (for SLL) — 0 percentage of participants
Oral Squamous Cell Carcinoma
Primary: Pathologic Response. — 25; 2; 4; 4 Participants
Pain
Primary: Time Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12) — 5.59; 37.08; 46.98; 52.45 Units on a scale — p=<0.001
Pulmonary Tuberculosis
Primary: Average Change Per Day (Slope) of Log Colony Forming Units (CFU) Counts From Day 0 to Day 14 (BACFU [0-14]) to Assess Bactericidal Activity — -0.039; -0.086; -0.065…
Coronavirus Disease 2019
Primary: Changes From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56. — -16.3; -8.1 units on a scale
Parkinson's Disease
Primary: Change in Score on the Part III Subscale of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) — 2.1; 4.2; -0.8; 3.9 Score on a scale…
Dengue Fever
Primary: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15 — 58.9; 15325.2; 5510.0; 11.2 titer
Migraine With or Without Aura
Primary: Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period. — -5.67; -3.5 days — p=0.4267
COVID-19
Primary: Overall Mortality — 22; 7 Participants
HIV/AIDS · Pre Hypertension
Primary: Change in Mean Systolic Blood Pressure (SBP) — -10.58; -4.65 mmHg — p=<0.0001
Diffuse Large B-cell Lymphoma
Primary: 1-year Progression-free Survival — 31 Participants
Healthy
Primary: Comparison of Minimum Percent Inhibition Platelet Reactivity Unit (PRU) Assessed by VerifyNow™ PRUTest™ From Baseline to Within 4 Hours After Study Drug Start. — -5.99…
Chronic Graft Versus Host Disease
Primary: Overall Response Rate at Week 16 (4 Weeks After the End of Treatment) — 88.9; 80.0 percentage of participants
SARS-CoV-2 Infection
Primary: Proportion of Patients With Any AE Within 7 d of Study Drug Infusion — 2; 1; 0; 0 Participants